Evidence map›Paper›PMID 39321900›Full record

ArticleInternational journal of pharmaceutics2024

Personalization of Intravaginal rings by droplet deposition modeling based 3D printing technology.

Nobel O Sierra-Vega, Sahar Rostom, Manjusha Annaji, Nahid Kamal, Muhammad Ashraf, Thomas O'Connor, Ahmed Zidan

Abstract read
In one paragraph

Article in International journal of pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nobel O Sierra-VegaOffice of Pharmaceutical Quality Research, CDER, U.S. FDA, USA.
Sahar RostomOffice of Pharmaceutical Quality Research, CDER, U.S. FDA, USA.
Manjusha AnnajiOffice of Pharmaceutical Quality Research, CDER, U.S. FDA, USA.
Nahid KamalOffice of Pharmaceutical Quality Research, CDER, U.S. FDA, USA.
Muhammad AshrafOffice of Pharmaceutical Quality Research, CDER, U.S. FDA, USA.
Thomas O'ConnorOffice of Pharmaceutical Quality Research, CDER, U.S. FDA, USA.
Ahmed ZidanOffice of Pharmaceutical Quality Research, CDER, U.S. FDA, USA. Electronic address: ahmed.zidan@fda.hhs.gov.

Funding

Intramural FDA HHS FD999999
6 · The paper itself

Abstract

Intravaginal rings (IVRs) are long-acting drug device systems designed for controlled drug release in the vagina. Commercially available IVRs employ a one-size-fits-all development approach, where all patients receive the same drug in similar doses and frequencies, allowing no space for dosage individualization for specific patients' needs. To allow flexibility for dosage individualization, this study explores the impact of infill-density on critical characteristics of personalized IVRs, manufactured using droplet deposition modeling three-dimensional (3D) printing technology. The model drug was dispersed on the surface of thermoplastic polyurethane pellets using an oil coating method. IVR infill-density ranged from 60 to 100 %. The compatibility of the drug and matrix was assessed using thermal and spectroscopic analyses. The IVRs were evaluated for weight, porosity, surface morphology, mechanical properties, and in vitro drug release. The results demonstrated high dimensional accuracy and uniformity of 3D-printed IVRs, indicating the robustness of the printing process. Increasing infill-density resulted in greater weight, storage modulus, Young's modulus, Shore hardness, and compression strength, while reducing the porosity of IVRs. All IVRs showed a controlled drug release pattern when tested under accelerated conditions of temperature for 25 days. Notably, greater infill-densities were associated with a decrease in the percentage of drug released. Overall, the study demonstrated that infill-density was an important parameter for personalizing the critical characteristics of the 3D-printed IVRs to fit individual patient needs.

Indexed as

Drug LiberationPolyurethanesPrinting, Three-DimensionalAdministration, IntravaginalContraceptive Devices, FemaleDelayed-Action PreparationsDrug Delivery SystemsFemaleHumansPorosityPrecision MedicineTechnology, PharmaceuticalDelayed-Action PreparationsPolyurethanes3D printingAdditive manufacturingDrug release personalizationInfill-densityIntravaginal ringsIVRMechanical properties

Identifiers

PMID39321900
PMCPMC12893198

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.